secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001437749-23-006382
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics terminates Chief R&D Officer Cavanagh; separation payment of $341,000
--------------------------------------------------------------------------------

- William Cavanagh III departed as Chief R&D Officer effective Feb 7, 2023; Separation Agreement effective Mar 10, 2023.
- Cavanagh receives $341,000 (12 months base salary) paid biweekly, plus health premium equivalent for one year.
- Separation includes full release of claims against the company and confidentiality/non-disparagement obligations.
- Stock options: unvested options terminate; vested options expire 90 days from Feb 7, 2023.
- Agreement includes 45-day consideration period and 7-day revocation period under ADEA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/0001437749-23-006382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/isr20230309_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-006382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer